Lantheus Holding Stock Price, News & Analysis

Lantheus Holdings (NASDAQ: LNTH) has announced it will host a conference call and webcast to discuss its Q4 and full year 2024 financial results on Wednesday, February 26, 2025, at 8:00 a.m. ET.

Participants are encouraged to register fifteen minutes before the scheduled start time through the company's investor relations website to avoid delays. A replay of the webcast will be available approximately two hours after the event and will remain accessible for at least 30 days on the same web page.

Lantheus Holdings (NASDAQ: LNTH) has announced upcoming presentations of piflufolastat F 18 (PYLARIFY) data at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco. Two key presentations will showcase PYLARIFY's capabilities: one focusing on early detection of recurrent prostate cancer in patients with minimal PSA levels, and another examining PYLARIFY's role in newly-diagnosed and recurrent prostate cancer patients based on registry data.

The presentations are scheduled for February 13, 2025, during Poster Session A, with studies from the University of California's Department of Radiation Oncology and Carolina Urologic Research Center. The research highlights PYLARIFY's effectiveness in real-world applications and its ability to detect prostate cancer recurrence in low PSA cases.

Lantheus Holdings (NASDAQ: LNTH) has appointed Dr. Phuong Khanh (P.K.) Morrow to its Board of Directors, effective February 1, 2025. Dr. Morrow, currently Head of the Oncology Therapeutic Area Unit at Takeda, brings extensive expertise in clinical development and oncology therapeutics. She will serve as a member of the Board's Science and Technology Committee.

This appointment marks the second new board addition in five months, bringing the total number of directors to eleven, with nine being independent. Dr. Morrow's previous roles include Chief Medical Officer at CRISPR Therapeutics and Vice President at Amgen, where she led global therapeutic areas in oncology and related fields. She holds an M.D. from the University of Texas Medical School at Houston and completed specialized training at prestigious institutions.

Lantheus Holdings (NASDAQ: LNTH) has announced a definitive agreement to acquire Evergreen Theragnostics for an upfront payment of $250 million, with potential additional milestone payments of up to $752.5 million. The acquisition aims to transform Lantheus into a fully integrated radiopharmaceutical company.

The deal brings significant strategic advantages, including enhanced manufacturing infrastructure, a revenue-generating CDMO business, and the addition of OCTEVY™, a registrational-stage diagnostic agent for neuroendocrine tumors that complements Lantheus' PNT2003 therapeutic candidate. The acquisition also expands Lantheus' oncology pipeline with multiple clinical and pre-clinical theranostic pairs.

The transaction is expected to close in the second half of 2025, subject to customary conditions and regulatory clearances. Lantheus has reaffirmed its FY 2024 guidance with revenue of $1.51-1.52 billion and adjusted fully diluted EPS of $6.65-6.70.

Lantheus Holdings (NASDAQ: LNTH) has announced a definitive agreement to acquire Evergreen Theragnostics for an upfront payment of $250 million, with potential additional milestone payments of up to $752.5 million. The acquisition aims to transform Lantheus into a fully integrated radiopharmaceutical company.

The deal brings significant strategic advantages, including Evergreen's scalable manufacturing infrastructure, CDMO services, and OCTEVY™, a registrational-stage diagnostic agent for neuroendocrine tumors that complements Lantheus' therapeutic candidate PNT2003. The acquisition also expands Lantheus' oncology pipeline with multiple clinical and pre-clinical theranostic pairs.

The transaction is expected to close in the second half of 2025, subject to customary conditions. Lantheus has reaffirmed its FY 2024 guidance with revenue of $1.51-1.52 billion and adjusted fully diluted EPS of $6.65-6.70.

Lantheus Holdings (NASDAQ: LNTH) has announced a $250 million share repurchase program to be executed over the next twelve months. The company plans to begin repurchases in Q4 2023 through open market transactions, private negotiations, and other legal means, with timing and amounts determined by management based on market conditions. The program demonstrates the board's confidence in Lantheus' leadership in radiopharmaceuticals and growth potential. The company aims to balance capital return to shareholders while pursuing business development opportunities to expand its radiopharmaceutical portfolio.

Lantheus Holdings (NASDAQ: LNTH), a leading radiopharmaceutical company, has announced its participation in the upcoming Jefferies London Healthcare Conference. Bob Marshall, Chief Financial Officer and Treasurer, will deliver a presentation on Wednesday, November 20, at 1:00 p.m. GMT (8 a.m. EST). The presentation will be accessible via live webcast through the Investors section of Lantheus's website. A replay will remain available for at least 30 days after the live event.

Lantheus Holdings (NASDAQ: LNTH) responds to CMS' updated payment rates for Calendar Year 2025 Medicare Hospital Outpatient Prospective Payment System. The new rules will 'unbundle' diagnostic radiopharmaceuticals, enabling separate payments for those costing over $630 per day. This change affects approximately 20% of traditional Medicare Fee for Service patients in hospital outpatient settings. PYLARIFY®, the company's PSMA PET imaging agent, is expected to exceed $1 billion in sales in 2024 and maintain its position as the #1 ordered PSMA PET imaging agent in the U.S. The new payment system will be effective January 1, 2025.

Lantheus (LNTH) reported strong Q3 2024 results with worldwide revenue of $378.7 million, up 18.4% year-over-year. PYLARIFY sales reached $259.8 million (+20.6%) and is on track to exceed $1 billion in 2024. DEFINITY sales grew 14.3% to $77.0 million. The company reported GAAP EPS of $1.79 and adjusted EPS of $1.70. Cash position strengthened to $866.4 million. The company narrowed its FY2024 guidance towards the higher end, projecting revenue of $1.51-1.52 billion and adjusted EPS of $6.65-6.70.